Conserved motif of hepatitis C virus E2/NS1 region
View Patent ↗Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). Also disclosed are immunogenic compositions comprising a pharmaceutically acceptable carrier and the fusion protein.
1. A fusion protein comprising an immunogenic polypeptide, wherein the immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8).
2. The fusion protein of claim 1 linked to a suitable carrier.
3. The fusion protein of claim 2 , wherein the fusion protein is linked to the carrier using a disulfide/amide-forming agent.
4. The fusion protein of claim 2 , wherein the fusion protein is linked to the carrier using a thio-ether-forming agent.
5. An immunogenic composition comprising a pharmaceutically acceptable carrier and the fusion protein of claim 1 .
6. The fusion protein of claim 2 , wherein the carrier is diphtheria toxoid.
7. The immunogenic composition of claim 5 , further comprising an adjuvant.